Get started
Dyadic International, Inc.Dyadic International, Inc.Dyadic International, Inc.

Dyadic International, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals

DYAI trade ideas

DYAI - big biotech smell trade - high risk / high AROMADyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1. abcnews.go.com 4th human case of bird flu linked to dairy cow outbreak: CDC The case was confirmed in a dairy worker in Colorado. Great news recentley for the company: Dyadic International, Inc. has struck a deal with Proliant Health and Biologicals to license its cutting-edge fungal production technology for manufacturing recombinant serum albumin. Dyadic stands to gain an initial $500,000, another half a million upon successful production strain transfer, and an additional $500,000 upon achieving a specified productivity level. Moreover, Dyadic will earn a share of the profits from Proliant’s sales of the animal-free product, marking a significant milestone in both companies’ commercial endeavors. Watching Dyadic International; Zacks Small-Cap Research Gives Stock $9 Price Valuation Dyadic Intl (NASDAQ: DYAI) and Proliant Health Biologicals to Launch $6 Billion Serum Albumin Market Product in 2025 Dyadic International And Proliant Health And Biologicals Announce Recombinant Albumin Development And Commercialization Partnership; Dyadic Will Receive An Upfront Milestone Payment Of $1.5M Disclaimer This content is for informational purposes only and should not be considered financial advice.
NASDAQ:DYAILong
by meitshels_smell_trades
DYAI Covid-19 Vaccine for the African ContinentDyadic International signed a COVID-19 vaccine technology transfer and licensing agreement with the Rubic Consortium. The Rubic Consortium is made up of promoters of the project representing public health, medical, academia, vaccine technology, technology transfer and economics sectors. Arrangement includes C1 COVID-19 vaccine technology transfer and licensing agreement. Provides potential funding pathway for a C1 manufactured COVID-19 vaccine to progress through Phase II and Phase III clinical trials. Establishes co-development basis for researching, developing and manufacturing multiple other C1 produced vaccines in addition to DYAI-100. Intends to reduce African dependence on foreign vaccine suppliers. Combined with previous C1 COVID-19 vaccine collaborations in India and South Korea (including Southeast Asia), this agreement further supports the potential for C1 produced COVID-19 immunization coverage to more than 40% of the world’s population. (rubicconsortium.co.za) Now what is the potential for DYAI??? The 52 Week Range is 3.1500 - 9.1900 Now the price is 3.89usd, so close to the lower end. The market cap is only 107Mil The biggest owner, 4.744%, is BlackRock Inc. which reported on 5/7/2021 1,307,205 shares on DYAI for a market value of $7.18Mil. if we make an average, Blackrock bought DYAI at 5.5usd per share. and i don`t think it will sell for less, especially with new COVID-19 vaccine coming. The second important owner is Vanguard Group Inc., which has 709,698 shares at a market value of $4.44Mil. they bought DYAI at 6.25usd and didn`t panic sell when the stock went to 2.5usd! My short term price target is 6.5usd, but on the long run, depending on the efficacy of the vaccine, this company can worth Billions! Just remember MRNA before it made 25X!
NASDAQ:DYAILong
by TopgOptions
1
Dyadic and Medytox To Develop Vaccines Against COVID-19 VariantsDyadic and Medytox To Develop Vaccines Against COVID-19 Variants Expanding existing COVID-19 vaccine research collaboration which began in July 2020. Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two or more of the current and future COVID-19 variants (e.g., tetravalent or quadrivalent COVID-19 vaccines) Exclusive license for Republic of Korea and multiple Southeast Asian countries, if successful Manufacturing protocols to produce vaccines from C1 have been successfully transferred and reproduced at Medytox finance.yahoo.com
NASDAQ:DYAI
by AlenCiken
DYAI (NASDAQ) - Be carefullGreetings Humbled, we would like to thanks for your support who has already liked, commented and followed us. Your support, strengthens us, to help in analyzing the market. If you have any questions, feel free to send us message (inbox). Pra Trading : - Please care for Money Management - Have a good psychology - Do not be hurry to open position and do not do nothing if u see opportunity - Evaluate and upgrade your trading plan Execution Strategy : - Know what you want to buy, see the Fundamental - Decide that you are on investing or speculating - Consider what your strategy based on Investing/Speculating - Make Road Map Of Your Trading Plan - Decide a. Entry strategy b. Cut loss c. Target of Profit Post Trading : a. Do not be sad if you loss or do not be very happy if you win b. Just become a normal without emotion, Do not put emotion into your trading c. Evaluate your trading d. Keep on Learning e. Be Humble Idea : DYAI (NASDAQ) - Be carefull
NASDAQ:DYAI
by MultiAssetX
BREAKOUT IMMINENT IN DYADIC INTERNATIONAL=====TARGET PRICE $8.25====== BREAKOUT LEVEL / ENTRY $7.10 COMPANY PROFILE Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. It focuses on further improving and applying its proprietary C1 technology, which is used in the discovery, development, and manufacture of biologic medicines and vaccines. The company was founded by Mark A. Emalfarb in 1979 and is headquartered in Jupiter, FL. Second quarter revenues increased 142% to $391,000 due to an increase in research collaborations. Total expenses in the period increased 70% to $3.4 million. Research and development1 was up 38% equaling $1.5 million. Greater activity with contract research organizations (CROs) and a greater number of research projects underway contributed to the increase. General and administrative expenses rose 103% to $1.9 million on higher stock compensation, annual bonuses and incentives, SEC registration and uplisting costs, business development and investor relation costs and legal expenses. Net loss was ($2.7) million for the period, compared to ($1.6) million in 2Q:18. On a per share basis, net loss was ($0.10) compared to ($0.06) in the prior year.
NASDAQ:DYAILong
by Bullishcharts